Abstract | OBJECTIVE: METHODS: Results of ESA therapy were analyzed in 163 MF patients with severe anemia, most of whom had inadequate erythropoietin (EPO) levels (<125 U/L) at treatment start. RESULTS: According to the revised criteria of the International Working Group for Myelofibrosis Treatment and Research, anemia response was achieved in 86 patients (53%). Median response duration was 19.3 months. In multivariate analysis, baseline factors associated with a higher response rate were female sex (P=.007), leukocyte count ≥10×109 /L (P=.033), and serum ferritin <200 ng/mL (P=.002). Patients with 2 or 3 of the above features had a significantly higher response rate than the remainder (73% vs 28%, respectively; P<.001). Over the 373 patient-years of follow-up on ESA treatment, nine patients developed thrombotic complications (six arterial, three venous), accounting for 2.41 events per 100 patient-years. Survival time from ESA start was longer in anemia responders than in non-responders (P=.011). CONCLUSION: Besides the already established predictive value of EPO levels, these data can help to identify which MF patients are more likely to benefit from ESA treatment.
|
Authors | Juan-Carlos Hernández-Boluda, Juan-Gonzalo Correa, Regina García-Delgado, Joaquín Martínez-López, Alberto Alvarez-Larrán, María-Laura Fox, Valentín García-Gutiérrez, Manuel Pérez-Encinas, Francisca Ferrer-Marín, María-Isabel Mata-Vázquez, José-María Raya, Natalia Estrada, Silvia García, Ana Kerguelen, María-Antonia Durán, Manuel Albors, Francisco Cervantes |
Journal | European journal of haematology
(Eur J Haematol)
Vol. 98
Issue 4
Pg. 407-414
(Apr 2017)
ISSN: 1600-0609 [Electronic] England |
PMID | 28009442
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Copyright | © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- EPO protein, human
- Hematinics
- Erythropoietin
- Ferritins
|
Topics |
- Aged
- Anemia
(blood, drug therapy, mortality)
- Disease-Free Survival
- Erythropoietin
(blood)
- Female
- Ferritins
(blood)
- Hematinics
(administration & dosage, adverse effects)
- Humans
- Leukocyte Count
- Male
- Middle Aged
- Primary Myelofibrosis
(blood, drug therapy, mortality)
- Sex Factors
- Spain
(epidemiology)
- Survival Rate
- Thrombosis
(blood, chemically induced, mortality)
|